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ABSTRACT
In the current study, an improved NGS approach was developed to study the B-cell repertoire evolution in
a simple mouse immunization model including only two DNA immunizations. The combination of 50RACE
and Ion Torrent long reads enabled unbiased immunoglobulin repertoire analysis even from
small amounts of peripheral mouse blood. The B-cell population expanded by the vaccine displayed a
relatively strong clonality. Upon priming with the ﬁrst vaccine dose, we observed a consistent pattern of V-
segment gene and CDR3 usage (public speciﬁcities). Interestingly, this pattern diversiﬁed with the second
dose of immunization —it was relatively different in individual mice in spite of having received the same
vaccine regimen (private speciﬁcities). Nevertheless, there were several instances in which the same public
V-segment genes and CDR3s that were expanded after the ﬁrst dose were further ampliﬁed after the
second immunization. Taken together, it appears that the major clonotypes expanded by vaccination
were originally a homogeneous subset that later diversiﬁed after a second dose leading to diverse
“private” clonal compositions in different mice. These results established a new platform valuable to
perform longitudinal analyses of the Ig germline gene usage and clonotype evolution throughout an
immunization regimen in a commonly used animal model.
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Introduction
Traditionally the humoral responses elicited by vaccines are
mainly monitored by the levels and quality of polyclonal antibod-
ies in serum and other speciﬁc tissues at various time points after
immunization. The introduction of monoclonal antibody (mAb)
technology enabled examining the quality of individual antibody
components in an immune serum including the immunoglobulin
(Ig) germline gene usage and sequence. However the process of
isolating mAbs is selective and does not necessarily reﬂect the full
picture of antibody responses. Next generation sequencing (NGS)
technology with its high-throughput analysis of a large pool of
genes at the same time, provides a powerful tool to investigate the
antibody repertoire with unprecedented efﬁciency and depth,
although the application of NGS to the study of antibody
responses following immunization needs to be further reﬁned.
B-cell repertoire NGS has been reported in the past few
years. In many instances, the samples are of human origin,1–4
although there have also been reports of primate5 and rabbit.6,7
In these studies, a multiplex PCR approach has proven sufﬁ-
cient to provide enough coverage of the different V-segment
genes without signiﬁcantly skewing the original repertoire as a
PCR artifact. In mice however, the number of different V-gene
segments is greater,8 and designing a primer set covering all the
possibilities is more challenging. In the current report,
50RACE,9 an appealing alternative to multiplex PCR, was used to
eliminate the need for bioinformatics corrections and also simplify
the PCR reactions required to obtain the amplicons to be
sequenced. We optimized the Ion Torrent10 platform which
enabled us to read over 400 bases from mouse 50RACE amplicons
in a single reverse read from the junction between variable and
constant region, thus covering the V-region from the end of
framework region 4 to the beginning of framework region 1. We
used HIV gp120 as a model antigen, since we have
previously shown gp120 DNA immunization of mice to be very
effective.11 Using this method, B-cell repertoire NGS was
conducted to monitor the dynamics of Ig germline gene usage and
clonotype expansion following immunizations in a mouse model.
Results
50RACE has been utilized to clone antibody genes from mouse
hybridomas,12 but it is yet to be established whether it would be
applicable to immunoglobulin repertoire sequencing by NGS.
In the current study, upon 50RACE and amplicon generation
by PCR, barcoded samples were run on the Ion Torrent PGM
platform (ThermoFisher Scientiﬁc). A signiﬁcant number of
reads covering the entire variable region after quality score
trimming was observed. A summary of the quality-ﬁltered
reads corresponding to each cell population and individual is
provided in Table S1. This method was then used in the current
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study to monitor the B cell repertoire evolution in a mouse
gp120 DNA immunization model.
The DNA vaccine was chosen in the current study because
our previous data demonstrated that DNA immunization with
an HIV-1 gp120-expressing plasmid leads to a measurable anti-
body response, and the avidity of the resulting antibodies
increases with subsequent doses.11 Furthermore, the gp120
DNA vaccine was more effective in priming germinal center
(GC) B cell responses than a recombinant gp120 protein vac-
cine with the same amino acid sequence.13 The immunization
schedule, sample collection and processing are depicted in
Fig. 1. There are only two groups in this simple pilot study.
Mice in Group A received two gp120-expressing DNA vaccine
immunizations on Days 0 and 21, followed with one recombi-
nant gp120 protein immunization 4 days before splenocytes
collection. Mice in Group B received the empty DNA vaccine
vector twice and one time gp120 protein immunization in the
same schedule as in Group A. No adjuvant was included for
either DNA or protein vaccines to minimize the impact of non-
antigen speciﬁc immune stimulations.
The ﬁrst sample collection on Day 7 consisted of peripheral
blood cells from a small volume of blood and did not require
euthanasia, so that the same animals could be subsequently
sampled. The protein inoculation was intended as a stimulus
for pre-existing memory cells elicited by DNA priming vaccina-
tion to migrate to the spleen and potentially differentiate into
plasmablasts. The second sample collection was 4 days after the
protein boost, and the differences in the immunoglobulin (Ig)
repertoire between the two groups could be attributed to the
expansion of B-cells mediated by two gp120 DNA immuniza-
tions and not to protein. It is not expected that a single small
dose of protein without adjuvant 4 days before the ﬁnal sample
collection could be immunogenic in vector control-immunized
mice. Indeed, there was no detectable gp120-speciﬁc antibody
response in the serum of Group B mice, whereas the gp120-
speciﬁc titer in Group A was high at the same time point (Fig.
S1). Both groups received the same gp120 protein dose and
serum was collected 4 days after protein inoculation.
The gp120 DNA-immunized mice in Group A showed
much greater diversity in their IgG heavy chain repertoires: 11
different germline genes were utilized (Fig. 2A). For kappa
reads the pattern is more similar between vector and gp120-
immunized (Fig. 2B). Interestingly, the germline gene distribu-
tion after the ﬁrst gp120 DNA immunization displayed a
“public” pattern in which germline gene usage was remarkably
consistent among ﬁve different mice in the same group. In con-
trast, empty vector-immunized mice in Group B displayed an
extremely polarized heavy V-segment gene usage repertoire in
peripheral blood cells after the ﬁrst DNA immunization. Only
3 germline genes were observed at more than 1% of the total
reads in gamma chain amplicons, and the vast majority of the
reads were assigned to a single germline gene per mouse.
Splenocytes were harvested on day 4 after protein vaccine
boost, and cells were sorted by FACS into two populations:
B220C CD138¡ and B220C CD138C. CD138 is a known plas-
mablast marker and its expression in B-cells is indicative of dif-
ferentiation into antibody secreting cells.14 A small number of
plasmablasts were observed in splenocytes from Group A mice
(Fig. S2 and Table S1), but no plasmablasts were observed in
Group B and therefore no sorting was performed on Group B
samples. Overall, fewer plasmablasts are expected in a vaccine
setting than after a viral infection.
It is interesting to observe that the gamma chain V-segment
gene usage was greatly diversiﬁed after the boost immunization.
Although the dominant V-segment genes observed after the
ﬁrst immunization were still heavily used by some mice after
the 2nd dose, the appearance of “private” V-segment gene usage
patterns was observed in certain individual mice, especially in
plasmablasts (Fig. 3). A very similar scenario was observed for
the kappa chain V-segment gene usage (Fig. 4). There was
manifest overlap between the repertoires of the individual mice
after the 1st DNA immunization in peripheral blood cells;
whereas with the 2nd DNA immunization and boost, the reper-
toires were more diversiﬁed and “private” V-segment gene
usage emerged.
When comparing the V-segment gene usage between plas-
mablasts and the B220C CD138¡ population after boost immu-
nization, we observed very different patterns (Fig. 5). These
samples were taken 4 days after protein inoculation, at which
time we expected the plasmablast expansion to reach its peak.
Thus, the B220C CD138¡ subpopulation represents B-cells that
have not been activated and may serve as a baseline, while the
B220C CD138C plasmablasts should represent antigen-speciﬁc
B-cells generated by the DNA priming vaccination that have
Figure 1. Schematic of the study design. Two DNA immunizations were administered by gene gun followed by a protein boost without adjuvant.
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been recently recalled to the spleen and activated by the protein
boost. There was a “public” gene usage pattern for gamma
reads: IGHV2-2 or IGHV2-3, and IGHV7-1 or IGHV7-3 were
exclusively over-represented in the plasmablast subpopulation
and not in the B220C CD138¡ B-cells or in the vector control-
immunized mice (Fig. 5 and Fig. S4). In order to obtain statisti-
cal signiﬁcance, two germline genes had to be clustered
together. This may seem arbitrary, but indeed the sequence of
the two genes clustered together is very similar, even at the
CDR1 and CDR2 regions (Supplemental Figure 5). Similarly,
for kappa reads IGKV6-23 was preferentially used by plasma-
blasts and not by B220C CD138¡ B-cells or splenocytes from
vector control group mice (Supplemental Figure 6).
The CDR3 sequence can be used as a clonotype marker.
Cells expressing the same CDR3 and V-segment gene are
very likely to have originated from a single precursor. When
the ranking of unique CDR3 amino acid sequences was
analyzed, we observed once more a pattern with shared
“public” CDR3s after the ﬁrst DNA prime for both gamma
and kappa chain reads (Fig. 6). After the boost, we observed
diversiﬁcation and the appearance of dominant “private”
CDR3s in the different mice (Fig. 7). Interestingly, there was
only one mouse in which 3 of the 5 dominant CDRH3s after
the ﬁrst DNA immunization went on to expand even further
after the boost (Fig. 7, blue).
The dominant CDRH3s after the 1st gp120 DNA immuniza-
tion (Fig. 6A) accounted for 77% of the total reads, with the top
5 accounting for 66%. This is indicative of a highly polarized
repertoire, probably antigen-speciﬁc, since the peripheral blood
cell sample was taken at the expected peak time of the B-cell
response. Further supporting the hypothesis that the dominant
CDRH3s observed after the 1st gp120 DNA immunization are
antigen-speciﬁc is the fact that none of the top 10 CDRH3s
found in this sample were observed in the vector control mice
Figure 2. A) V-gene segment usage in gamma reads from peripheral blood cells of vector control-immunized mice and gp120-immunized mice. The distribution in vector
control-immunized mice is oligoclonal and very different from that of gp120-immunized mice. B) Same as A, but in kappa reads.
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(data not shown). However, a different scenario was observed
for the kappa chain CDRL3s: the top 5 CDRL3s only accounted
for 28% of the reads on average (Fig. 6B). In addition, all ﬁve
dominant CDRL3s were observed in the vector control mice,
albeit at lower frequencies (data not shown). This discrepancy
between gamma and kappa chain is probably explained by the
fact that the gamma chain reads are undoubtedly derived from
cells expressing IgG, as the reverse primers were speciﬁcally
designed to amplify IgG heavy chain cDNA and not any other
subclasses. On the other hand, the kappa reverse primers would
also amplify kappa chain cDNA originating from cells express-
ing any subclass from their heavy chain locus. Therefore, while
the heavy chain reads are derived exclusively from IgG-express-
ing cells, the kappa chain reads reﬂect a combination of B-cells
Figure 3. Comparison of the gamma chain V-segment germline gene usage by IgG expressing B-cells in peripheral blood cells 7 days after the ﬁrst DNA immunization or
in spleen plasmablasts 4 days after the 2nd DNA and boost. Germline genes which are dominant in both time points are highlighted.
Figure 4. Comparison of the V-segment kappa germline gene usage by B-cells in peripheral blood cells 7 days after the ﬁrst DNA immunization or in spleen plasmablasts
4 days after the 2nd DNA and boost. Germline genes which are dominant in both time points are highlighted.
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from every subclass, and thus the enrichment in antigen-spe-
ciﬁc kappa reads is diluted by contributions from na€ıve IgM/
IgD-expressing cells. After the boost immunization, IgM-
expressing B-cells were removed from the splenocyte cell sus-
pension using magnetic beads, and therefore most kappa reads
should derive from IgG-expressing cells.
When looking at the dominant CDR3 repertoire in plas-
mablasts after boost, we observed “private” patterns for both
gamma and kappa as opposed to the “public” patterns seen
after the 1st immunization (Fig. 7). This is consistent with
the patterns observed for V-segment gene usage described
above.
Discussion
Prior to NGS, B-cell repertoires have been studied by tradi-
tional sequencing techniques with isolated B-cells of interest
or hybridoma cells, but these techniques were insufﬁcient for
creating a high-resolution proﬁle of the Ig gene usage. It is
important to monitor the immune cell population dynamics
after antigen stimulation and to establish patterns of variable
gene utilization, and to correlate them with the nature of the
antigen design. In the current study, we established the feasi-
bility of using NGS to conduct B-cell repertoire analysis with
peripheral blood samples in addition to splenocytes. Reddy
and others have been able to obtain immunoglobulin reper-
toires from mouse bone marrow and spleen.15–18 These two
sources are no doubt very relevant, however sampling these
organs is a terminal procedure and in order to establish B-cell
dynamics, repetitive sampling is required. To the best of our
knowledge this is the ﬁrst report of a methodology that ena-
bles sequencing the immunoglobulin repertoire from a small
volume of mouse peripheral blood. This is of great impor-
tance, since variation between individuals is very high after
several instances of exposure to antigen. Thus, our methodol-
ogy enables establishing a time course of the B-cell repertoire
evolution in a mouse model.
One key ﬁnding was that upon the ﬁrst dose of DNA immuni-
zation, there was a remarkable overlap in the IgG repertoire of the
5 different mice. Other studies have shown much lower degrees of
overlap in cells from different individual mice.15 This is probably
due to the fact that in those studies spleen or bone marrow sam-
ples were analyzed after multiple immunizations, whereas in the
present report we were able to analyze peripheral blood samples
shortly after the ﬁrst immunization. We believe that both the sam-
pling timing and the nature of the vaccine can greatly inﬂuence
the composition of the B-cell repertoire. The peak of the plasma-
blast response has been observed before at 4 days post-immuniza-
tion in secondary lymphoid organs.19 We expected the expansion
of vaccine-induced B-cells to be maximal at that time. We hypoth-
esized that by sampling the repertoire at that time, any variations
from an unimmunized control would likely reﬂect the selection
and expansion of antigen-speciﬁc cells.
Figure 5. Relative abundance of germline gene assignments in two subpopulations—plasmablasts (B220CCD138C) or other B cells (B220CCD138¡)—from mice immu-
nized with two doses of gp120 DNA. Each color represents an individual mouse. 4 out of 5 mice showed increased germline gene usage in plasmablasts for either one or
both of the germline genes shown. P value denotes statistical signiﬁcance of a 2-way ANOVA for the variable “subpopulation” (plasmablasts vs. CD138¡ B cells) for the
gamma chain, or for a paired one-tailed t-test for the kappa chain.
Figure 6. A: Relative frequencies of the dominant CDRH3s from gamma reads after
the 1st immunization. None of the dominant CDRH3s were observed in vector con-
trol-immunized mice. B: Relative frequencies of the dominant CDRL3s from kappa
reads after the 1st immunization. All of the dominant CDRL3s in gp120-immunized
mice were also present in vector control-immunized mice, albeit at lower frequen-
cies (data not shown).
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In contrast with the observations after one dose, upon boost
we ceased to observe such a large degree of overlap between
individuals, consistent with published observations.15 This
transition from a public repertoire after one dose to mostly pri-
vate repertoires after the second dose was quite remarkable and
unexpected. It is possible that DNA vaccines produce a very
homogeneous form of antigen and therefore the B-cells in the
na€ıve repertoire that can be selected through binding are more
limited than if a more heterogeneous antigen were presented,
such as a recombinant protein or virus-based vaccine, which
may include denatured or partially degraded forms of antigen,
or mixed antigens. In the current study, spleens were harvested
only 4 days after protein boost, and therefore we do not antici-
pate that the protein boost had a signiﬁcant effect on remodel-
ing the B-cell repertoire, rather, it was intended as a means to
recall to the spleen the memory B-cells generated after the 2nd
dose of DNA.
Alternatively, we can speculate that upon a ﬁrst encounter
with antigen there are only a limited number of unique na€ıve
B-cell clones that are stimulated to expand, and even fewer
antigen-speciﬁc clones undergo class switching and expand
enough to be above our detection threshold. There could be
other clones that are initially undetected due to their small
numbers, who upon re-encounter with antigen accumulate
more somatic mutations that enable them to compete with
the clones that expanded more strongly after the ﬁrst dose.
This later process of somatic mutation and selection may be
more stochastic and thus lead to the observed private reper-
toires when comparing among individuals after the second
DNA dose. Further studies and larger numbers of mice and
sampling time points will be needed in order to conﬁrm this
hypothesis.
However, some bias may be introduced by this method due
to the small sample size. It is known that terminally differenti-
ated B-cells produce more immunoglobulin RNA than naive or
memory cells.20 Since NGS repertoire analysis measures cDNA,
the fact that some cells in a mixed population express more
RNA than others could confound the relationship between the
fraction of reads in the NGS data set and the cellular composi-
tion of the original repertoire. We have attempted to minimize
this problem by sorting cells that are known to produce larger
amounts of immunoglobulin RNA, such as plasmablasts. This
allowed for a more detailed analysis of the B cell repertoire in
our study. Unfortunately, sorting cells from a small volume of
mouse peripheral blood is not technically feasible at this point
and requires further methodology development. This led to the
shortcoming of the current study that plasmablast samples were
collected only once (after 2nd immunization) and they were com-
pared against B-cells collected from peripheral blood after the
ﬁrst immunization. More systematic longitudinal analyses of the
B-cell repertoire in peripheral blood after immunization in a vac-
cine regimen with more doses are warranted. In addition, the
data collected from the current study may be affected by using
gp120 as the immunogen or plasmid DNA plasmid as the for-
mat of vaccines. It would also be interesting to see whether the
initial public and subsequent private repertoire patterns observed
here also applied to other antigens and vaccine modalities.
In future studies, monoclonal antibodies (mAbs) can be iso-
lated from the same study design with known sequence and
serve as leads to mine the immune repertoire in search of reads
with similar V-genes and CDRs to identify new functional anti-
bodies. This would also enable the assessment of any novel
vaccine’s capability to elicit antibodies similar to lead mAbs of
interest. In addition, extensive analysis of somatic mutation at
different time points also enables tracing evolutionary pathways
for ﬁnal functional antibodies. In this way, novel vaccines can
be designed and studied with much greater precision to achieve
the desired immune responses and protection.
Materials and methods
Animals
C57BL/6 female 6–8 week old mice were purchased from the
Jackson Laboratory and maintained in the Department of Ani-
mal Medicine at the University of Massachusetts Medical
School in accordance with the “Guide for the Care and Use of
Laboratory Animals” (National Research Council). All proto-
cols have been reviewed and approved by the Institutional Ani-
mal Care and Use Committee (IACUC).
DNA immunization
DNA immunizations were performed using a Helios Gene Gun
(Bio-Rad) as described before21 following the schedule shown
Figure 7. The relative frequency of CDR3s common to two or more mice (“public”
CDR3s) after 1 or 2 gp120 DNA doses. Each color represents an individual mouse.
Top: public CDRH3s for IgG-expressing B cell heavy chain. After the ﬁrst immuniza-
tion all public CDRH3s appeared at a very similar frequency in all 5 mice, whereas
after the second DNA immunization the scatter was considerable—each individual
mouse displayed different frequencies of the different public CDRH3s. Bottom:
public CDRL3s for B-cells expressing kappa chain. CQQYSSYPLTF is a rare CDRL3
after the ﬁrst immunization that goes on to become dominant and shared by 3
out of 5 mice.
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in Fig. 1. 3.6 ug of plasmid DNA encoding gp120-JRFL or
empty expression vector (pJW4303) were administered per
mouse and per immunization.
Protein inoculation
HIV-1 gp120 JR-FL protein was produced by transient
transfection of 293F cells with the vaccine construct using
the 293Freestyle system (Thermo Fisher Scientiﬁc). Super-
natants were collected 72 hours post-transfection and gp120
JR-FL was puriﬁed over a lentil lectin agarose afﬁnity col-
umn (GE Healthcare). 50 ug per mouse of puriﬁed protein
dissolved in PBS were administered intraperitoneally in the
absence of adjuvant 4 days prior to euthanasia and spleen
collection.
Peripheral blood cell collection
Seven days after the 1st DNA vaccination, peripheral blood
cells were isolated from whole blood as follows. Whole blood
was obtained by facial vein puncture: 150 uL were collected
into potassium EDTA microtainers (BD Biosciences) and
passed through heparinized hematocrit capillary tubes at the
time of collection. Blood was transferred to 1.5 mL polypro-
pylene centrifuge tubes and after centrifugation at 1,000 xg
for 10 min @ 4C, the supernatant (plasma) was stored at
¡20C to be later assayed for the presence of anti-gp120 anti-
bodies by ELISA. The soft cell pellet was resuspended in 50
uL rat normal serum and 900 uL Hanks Balanced Salt Solu-
tion (HBSS, Mediatech) with 2% FCS, 1mM EDTA, without
Ca2C or Mg2C. After a 5-minute incubation period at room
temperature, 2.5 ug (5 uL) of biotinylated TER-119 (BD bio-
sciences) was mixed in and incubated for 10 minutes at room
temperature. Next, 25 uL of Streptavidin RapidSpheres
(Stemcell Technologies) were added, mixed in, and incubated
3 minutes at room temperature. Tubes were placed on a mag-
netic rack (Thermo Fisher Scientiﬁc) and let stand for 3–4
minutes until the beads were visibly clumped on the side.
Collected the supernatant and centrifuged at 1,000 xg for
10 min at 4C. Resuspended in 200 uL of red blood cell lysis
buffer (Sigma) and incubated for 3 minutes on ice. Quenched
with 1 mL HBSS 2% FCS 1mM EDTA and pelleted cells at
1,000 xg for 10 min at 4C. Removed the supernatant and
lysed the pellet with 0.5 mL of TRIzol reagent (Thermo Fisher
Scientiﬁc) for 5 minutes at room temperature. Added 100 uL
of chloroform, mixed vigorously, and centrifuged at 12,000 xg
for 15 min at 4C. Moved the aqueous phase to a new tube
and added 0.5 volumes of 200-proof ethanol and mixed.
Loaded the mix into a Quick-RNA MicroPrep column (Zymo
Research) and centrifuged for 30 seconds at 12,000 xg at
room temperature. Washed column with 400 uL RNA prep
buffer, 700 uL RNA wash buffer, once again with 400 uL
RNA wash buffer, and spun at 12,000 xg for 2 minutes.
Transferred the column into a new 1.5 mL RNase-free collec-
tion tube and pipetted 10 uL RNase-free water onto the mem-
brane. After 3 minutes at room temperature, spun down at
12,000 xg for 1 minute. Stored at ¡80C until 50RACE was
performed.
ELISA
ELISA for the detection of gp120-speciﬁc antibody in plasma or
serum samples was conducted as previously described.11 Plates
were coated with the same gp120-JR-FL used for protein
inoculation.
Cell staining, magnetic separation and FACS sorting
Spleens were removed after mouse euthanasia and placed on
petri dishes with 10 mL RPMI 1640 10% FCS (Thermo Fisher
Scientiﬁc). Single cell suspensions were obtained by pressing
the tissue through a 70 micron nylon mesh into 50 cc conical
tubes. The suspension was topped off to 50 mL with RPMI
1640 10% FCS, and centrifuged at 350 xg for 5 minutes at 4C.
The cell pellet was resuspended in Hanks Balanced Salt Solu-
tion (HBSS, Mediatech) with 2% FCS, 1mM EDTA, without
Ca2C or Mg2C (FACS buffer), moved to a 15 mL conical tube,
and cells were counted and their density adjusted. For every
100 million cells resuspended in 1 mL the following were
added: 8 ug (2 uL) 2.4G2 monoclonal antibody (rat anti-mouse
FcgRII/III, BioXcell), and 50 uL normal rat serum. Incubated
at room temperature for 3 minutes. Added the following bioti-
nylated antibodies and incubated samples 10 minutes at room
temperature: 5 ug (10 uL) TER-119 (BD Biosciences), 5 ug (10
uL) Hamster anti-mouse CD3epsilon (BD Biosciences) and
5 ug (10 uL) Goat anti-mouse IgM (Southern Biotech). Added
125 mL of Streptavidin RapidSpheres (Stemcell Technologies)
and incubated at room temperature for 2.5 minutes. Topped
up to 5 mL with column buffer, mixed and placed the tube into
“the Big Easy silver EasySep magnet” (Stemcell Technologies)
for 2.5 minutes. Supernatants containing the depleted samples
were decanted into new 50 mL tubes and topped up to 20 mL
with ice-cold FACS buffer and kept on ice. Group B samples
contained 5–8 million cells, which were pelleted and lysed in
TRIzol and frozen at ¡80C until sorting of group A samples
was ﬁnished and RNA extraction was performed. Group A
samples were resuspended in FACS buffer at 30 million cells/
mL and the following antibodies were added: Biotin-anti-
mouse CD138 (BD Biosciences; 100 ng/million cells), V450 Rat
Anti-Mouse CD45R (B220) (clone RA3-6B2, BD Biosciences;
40 ng/million cells). Cell suspensions were incubated for
30 min on ice in the dark, topped up to 50 mL with ice-cold
PBS, spun down at 4C and 400 £ g for 5 min supernatants
were discarded. Cell pellets were again resuspended as above
and Neutravidin-PE was added (Thermo Fisher Scientiﬁc;
100 ng/million cells). Cells were incubated on ice overnight.
Topped up to 50 mL with ice-cold FACS buffer, spun down at
4C and 400 £ g for 5 minutes and discarded supernatants.
Repeated once. Resuspended the cell pellets in 1 mL staining
buffer and moved to 12 £ 75 mm tubes; kept at 4C until sort-
ing time. Cells were sorted into B220CCD138C (plasmablasts)
and B220CCD138¡ (B-cells) by FACS using a FACS Aria II
(BD Biosciences). After sorting, plasmablast samples contained
1 to 2,000 cells, whereas B220CCD138¡ B cell samples con-
tained 2 to 5 million cells. Sorted samples were centrifuged and
the cell pellets were lysed in TRIzol and chloroform was added
according to the manufacturer’s recommendations (Thermo
Fisher Scientiﬁc). 0.2 mL Chloroform were added per 1 mL of
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TRizol lysate and vigorously mixed. After centrifugation at
12,000 xg for 15 min at 4C, moved the aqueous phase to a new
tube and added 0.5 volumes of 200-proof ethanol and mixed.
Group A B220CCD138¡ B cell samples and group B samples
were loaded into an RNEasy Mini Kit column (Qiagen), washed
according to manufacturer’s instructions, and RNA was
eluted in 25 uL of water. Group A plasmablast samples were
loaded into a Quick-RNA MicroPrep column (Zymo Research)
and processed as described above for peripheral blood samples.
RNA was stored at ¡80C until 50RACE was performed.
50RACE and amplicon generation
50RACE was performed using the template switch method.22
Single-stranded cDNA (sscDNA) synthesis was carried out
using the Mint-2 50RACE Kit (Evrogen) according to the man-
ufacturer’s instructions starting from 3 uL of RNA. sscDNA
was puriﬁed using 1.8x volumes of AMPure XP beads (Beck-
man Coulter), washed once with 200 uL 70% Ethanol and
eluted in 45 uL water.
The fragments to be sequenced were generated by PCR
using speciﬁc reverse primers and a universal forward primer
which anneals to the sequence introduced by template switch
during 50RACE. In addition, the PCR primers used were fused
to the adapters necessary for Ion Torrent template preparation
(Adapter full-length P1 and adapter A, Thermo Fisher Scien-
tiﬁc). All primers were added from a stock solution at 10 uM.
Amplicons were generated by PCR using the Kapa HotStart
HiFi kit (Kapa Biosystems) following manufacturer’s instruc-
tions. Template volumes, annealing temperatures, and exten-
sion times were optimized for the different reactions. For
kappa V-region, 1.3 uL ampliﬁcation primers FLP1-M1 and
mKappa-AdA with an IonXpress barcode were used, along
with 5 uL template (puriﬁed sscDNA) in a ﬁnal volume of 40
uL. The annealing temperature was 62C; extension for 20 s at
72C; 30 cycles were performed. The PCR reaction was loaded
in a 1.5% agarose gel and the amplicon band at approximately
600 bp was cut and puriﬁed with a NucleoSpin Gel and PCR
Clean-up kit (Macherey-Nagel, Bethlehem, PA) eluting in 15
uL water. Due to the diversity of the gamma chain constant
region sequence in the vicinity of the variable region for the dif-
ferent IgG subclasses, two reverse primers were necessary: the
IgG2b reverse primer covered IgG1, IgG2a, and IgG2b sequen-
ces; while the IgG3 reverse primer was speciﬁc for IgG3. Thus,
two separate PCR reactions were conducted to amplify gamma
chain V-region amplicons: one with IgG2b and one with IgG3
reverse primer. Gamma chain V-region amplicons were ampli-
ﬁed in two phases: ﬁrst, adding 1.7 uL M1 primer (from Mint-2
kit, Evrogen) and mIgC-179 reverse (which covered all IgG
subclasses), along with 10 uL template (puriﬁed sscDNA) in a
ﬁnal volume of 50 uL. The annealing temperature was 62C,
extension for 20 s at 72C; 10 cycles. The entire PCR reaction
volume was puriﬁed with 0.8x volumes (40 uL) of SPRI size
select beads (Beckman Coulter), washed once with 200 uL 85%
Ethanol and eluted in 20 uL water. 19 uL of this eluate was
used in a second round of PCR with primer FLP1-M1 and
mIgG2b-AdA or IgG3-AdA with an IonXpress barcode, in a
ﬁnal volume of 40 uL. The annealing temperature was 62C,
extension for 20 s at 72C, 25 cycles. The PCR reaction was
loaded in a 1.5% agarose gel and the amplicon band at approxi-
mately 650 bp was cut and puriﬁed with a NucleoSpin Gel and
PCR Clean-up kit (Macherey-Nagel), eluting in 15 uL water.
Primer sequences (50 to 30): M1: AAGCAGTGGTATCAACG-
CAGAGT, FLP1-M1: CCACTACGCCTCCGCTTTCCTCTCT
ATGGGCAGTCGGTGATAAGCAGTGGTATCAACGCA-
GAGT, mIgC-179 reverse: CAGACTGCAGKASAGMTG;
mIgG2b-AdA: CCATCTCATCCCTGCGTGTCTCCGACTC
AGctaaggtaacGATAGGGGCCAGTGGATAGACTGATGG
(the lowercase letters represent the IonXpress barcode
sequence, in this case IonXpress_001); mIgG3-AdA: CCATCT-
CATCCCTGCGTGTCTCCGACTCAGtaaggagaacGATAGG-
GACCAAGGGATAGACAGA (the lowercase letters represent
the IonXpress barcode sequence, in this case IonXpress_002);
mKappa-AdA: CCATCTCATCCCTGCGTGTCTCCGACT-
CAGaagaggattcGATGGATACAGTTGGTGCAGCAT (the
lowercase letters represent the IonXpress barcode sequence, in
this case IonXpress_003).
Library preparation
Puriﬁed amplicons were subjected to 2 rounds of size selection
using 0.6x volumes of SPRI size select beads (Beckman Coulter)
and eluted in 15 uL of water. Concentrations were measured
using the Qubit HS dsDNA kit (Thermo Fisher Scientiﬁc).
IgG1/2a/2b amplicons (ampliﬁed with IgG2b-AdA reverse
primer) and IgG3 amplicons (ampliﬁed with IgG3-AdA reverse
primer) were mixed 1:1, and the mix was in turn mixed in equi-
molar amounts with the kappa chain amplicons. Concentra-
tions were adjusted to 50 pM and the mix was used to template
IonSphere Particles using the Ion PGM Template IA 500 Kit
(Thermo Fisher Scientiﬁc) following manufacturer’s instruc-
tions. Templated particles were enriched using an Ion One-
Touch Enrichment System (Thermo Fisher Scientiﬁc).
Sequencing
Enriched templated Ion Sphere Particles prepared as shown
above were annealed to the sequencing primer and bound to
the sequencing polymerase using an Ion PGM Hi-QTM OT2 kit
(Thermo Fisher Scientiﬁc), and loaded into Ion 318 chips and
sequenced using an Ion Torrent PGM instrument (Thermo
Fisher Scientiﬁc) following the manufacturer’s instructions but
increasing the ﬂow number to 1,350 ﬂows.
Data analysis
Fastq ﬁles were downloaded from the Ion Torrent server
(Thermo Fisher Scientiﬁc) after running the ﬁle generator
plugin and reads over 400 bases long and with phred quality
score >20 were selected using the AbMining toolbox suite.23
The output fasta ﬁle was split into blocks of 500,000 reads and
submitted to the IMGT High V-quest server.24 The output data
were clustered into clonotypes based on unique CDR3 and V-
gene usage. Lists of unique V-genes and CDR3s were generated
using the advanced ﬁlter function in Microsoft Excel and their
relative frequencies were calculated with the COUNTIF func-
tion. BLASTC25 was utilized to generate pairwise alignments of
the unique CDR3s from different mice. Shared CDR3s were
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identiﬁed in this way and their relative proportions for each
individual mouse and time point were plotted. All plotting and
statistical analyses were carried out in GraphPad Prism.
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